表紙:世界の抗凝固拮抗薬市場:世界業界分析、規模、シェア、成長、動向、予測
市場調査レポート
商品コード
812826

世界の抗凝固拮抗薬市場:世界業界分析、規模、シェア、成長、動向、予測

Anticoagulant Reversal Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

出版日: | 発行: Transparency Market Research | ページ情報: 英文 156 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.57円
世界の抗凝固拮抗薬市場:世界業界分析、規模、シェア、成長、動向、予測
出版日: 2019年02月21日
発行: Transparency Market Research
ページ情報: 英文 156 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の抗凝固拮抗薬市場について調査し、市場の動向とセグメント別動向、地域別予測、市場に参入する企業のプロファイルについてまとめています。

第1章 序論

第2章 仮定と略語

第3章 調査方法

第4章 エグゼクティブサマリー

第5章 市場概要

  • 製品概要
  • 市場動向
    • 促進因子
    • 阻害因子
    • 機会
    • 市場価値
    • 市場見通し
    • 主な業界動向
    • 法規制シナリオ
    • 償還シナリオ
    • パイプライン分析
    • 医療概要

第6章 製品別市場分析

  • イントロダクション
  • 市場価値シェア
  • 市場価値予測
    • ビタミンK
    • プロタミン
    • トラネキサム酸
    • Idarucizumab
    • Andexxa
    • その他
  • 市場の魅力度

第7章 流通チャネル別市場分析

  • イントロダクション
  • 市場価値シェア
  • 市場価値予測
    • 院内薬局
    • 小売薬局
    • その他
  • 市場の魅力度

第8章 地域別市場分析と予測

  • イントロダクション
  • 市場価値分析
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力度

第9章 北米

第10章 欧州

第11章 アジア太平洋地域

第12章 ラテンアメリカ

第13章 中東・アフリカ

第14章 競合環境

  • 競合マトリクス
  • 市場シェア分析
  • 企業プロファイル
    • Bausch Health Companies, Inc.
    • Pfizer, Inc.
    • Fresenius Kabi AG
    • Amneal Pharmaceuticals, Inc.
    • Boehringer Ingelheim GmbH
    • CSL Limited
    • Octapharma AG
    • Portola Pharmaceuticals, Inc.
    • Perosphere Pharmaceuticals, Inc.
図表

List of Tables

  • Table 01: Reimbursement Scenario for AndeXXa
  • Table 02: Reimbursement Scenario for Praxbind
  • Table 03: Reimbursement Scenario for Kcentra
  • Table 04: Pipeline Analysis
  • Table 05: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2016-2026
  • Table 06: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 07: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Region, 2016-2026
  • Table 08: North America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Country, 2016-2026
  • Table 09: North America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2016-2026
  • Table 10: North America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 11: Europe Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 12: Europe Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2016-2026
  • Table 13: Europe Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 14: Asia Pacific Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 15: Asia Pacific Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2016-2026
  • Table 16: Asia Pacific Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 17: Latin America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 18: Latin America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2016-2026
  • Table 19: Latin America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 20: Middle East & Africa Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 21: Middle East & Africa Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2016-2026
  • Table 22: Middle East & Africa Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2016-2026

List of Figures

  • Figure 01: Anticoagulant Reversal Drugs Market Size (US$ Mn) and Distribution, by Region, 2017 and 2026
  • Figure 02: Global Anticoagulant Reversal Drugs Market Size (US$ Mn) and Forecast, 2018-2026
  • Figure 03: Market Value Share, by Product (2018)
  • Figure 04: Market Value Share, by Distribution Channel (2018)
  • Figure 05: Market Value Share, by Region (2018)
  • Figure 06: Regulatory Approval Process - U.S.
  • Figure 07: Regulatory Approval Process - Europe
  • Figure 08: Regulatory Approval Process - Japan
  • Figure 09: Global Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2017 and 2026
  • Figure 10: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Prothrombin Complex Concentrates (PCC) 2016-2026
  • Figure 11: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Vitamin K, 2016-2026
  • Figure 12: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Protamine, 2016-2026
  • Figure 13: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Tranexamic Acid, 2016-2026
  • Figure 14: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Others, 2016-2026
  • Figure 15: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Idarucizumab, 2016-2026
  • Figure 16: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by AndeXXa, 2016-2026
  • Figure 17: Global Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2018-2026
  • Figure 18: Global Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 19: Global Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2018-2026
  • Figure 20: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Hospital Pharmacies, 2016-2026
  • Figure 21: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Retail Pharmacies, 2016-2026
  • Figure 22: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Others, 2016-2026
  • Figure 23: Global Anticoagulant Reversal Drugs Market Value Share, by Region, 2017 and 2026
  • Figure 24: Global Anticoagulant Reversal Drugs Market Attractiveness, by Region, 2018-2026
  • Figure 25: North America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016-2026
  • Figure 26: North America Anticoagulant Reversal Drugs Market Value Share Analysis, by Country, 2017 and 2026
  • Figure 27: North America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Country, 2018-2026
  • Figure 28: North America Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2017 and 2026
  • Figure 29: North America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2018-2026
  • Figure 30: North America Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 31: North America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2018-2026
  • Figure 32: Europe Anticoagulant Reversal Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016-2026
  • Figure 33: Europe Anticoagulant Reversal Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 34: Europe Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2018-2026
  • Figure 35: Europe Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2017 and 2026
  • Figure 36: Europe Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2018-2026
  • Figure 37: Europe Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 38: Europe Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2018-2026
  • Figure 39: Asia Pacific Anticoagulant Reversal Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016-2026
  • Figure 40: Asia Pacific Anticoagulant Reversal Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 41: Asia Pacific Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2018-2026
  • Figure 42: Asia Pacific Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2017 and 2026
  • Figure 43: Asia Pacific Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2018-2026
  • Figure 44: Asia Pacific Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 45: Asia Pacific Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2018-2026
  • Figure 46: Latin America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016-2026
  • Figure 47: Latin America Anticoagulant Reversal Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 48: Latin America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2018-2026
  • Figure 49: Latin America Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2017 and 2026
  • Figure 50: Latin America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2018-2026
  • Figure 51: Latin America Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 52: Latin America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2018-2026
  • Figure 53: Middle East & Africa Anticoagulant Reversal Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016-2026
  • Figure 54: Middle East & Africa Anticoagulant Reversal Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 55: Middle East & Africa Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2018-2026
  • Figure 56: Middle East & Africa Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2017 and 2026
  • Figure 57: Middle East & Africa Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2018-2026
  • Figure 58: Middle East & Africa Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 59: Middle East & Africa Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2018-2026
  • Figure 60: Global Anticoagulant Reversal Drugs Market Share Analysis, by Company (2018)
  • Figure 61: Product Overview - Bausch Health Companies, Inc.
  • Figure 62: Breakdown of Net Sales (%), by Region, 2017 - Bausch Health Companies, Inc.
  • Figure 63: Revenue (US$ Mn), 2015-2017 - Bausch Health Companies, Inc.
  • Figure 64: R&D Expenses (US$ Mn), 2015-2017 - Bausch Health Companies, Inc.
  • Figure 65: Product Overview - Pfizer, Inc.
  • Figure 66: Breakdown of Net Sales, by Region, 2017 - Pfizer, Inc.
  • Figure 67: Revenue (US$ Bn) and Y-o-Y Growth (%), 2013-2017 - Pfizer, Inc.
  • Figure 68: R&D Intensity and Sales & Marketing Intensity - Company Level, 2016-2017 - Pfizer, Inc.
  • Figure 69: Product Overview - Fresenius Kabi AG
  • Figure 70: Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017 - Fresenius Kabi AG
  • Figure 71: Breakdown of Net Sales, by Region, 2017 - Fresenius Kabi AG
  • Figure 72: Breakdown of Net Sales, by Segment, 2017 - Fresenius Kabi AG
  • Figure 73: Research & Development Cost, 2016 - 2017 (US$ Mn) - Fresenius Kabi AG
  • Figure 74: Product Overview - Amneal Pharmaceuticals, Inc.
  • Figure 75: Product Overview - Boehringer Ingelheim GmbH
  • Figure 76: Revenue (US$ Bn) and Y-o-Y Growth (%), 2014-2017 - Boehringer Ingelheim GmbH
  • Figure 77: Breakdown of Net Sales, by Business and Business Segment Level, 2017 - Boehringer Ingelheim GmbH
  • Figure 78: Breakdown of Net Sales, by Region (Company Level), 2017 - Boehringer Ingelheim GmbH
  • Figure 79: R&D Expenditure (US$ Bn), 2013-2017 - Boehringer Ingelheim GmbH
  • Figure 80: Product Overview: CSL Limited
  • Figure 81: Total Revenue (US$ Mn) and Y-o-Y Growth, 2016-2018 - CSL Limited
  • Figure 82: R&D Investment, (US$ Mn) and Y-o-Y Growth, 2016-2018 - CSL Limited
  • Figure 83: Sales Revenue (US$ Mn) and Y-o-Y Growth, 2016-2018 - CSL Limited
  • Figure 84: Net Profit (US$ Mn), 2016-2018 - CSL Limited
  • Figure 85: Product Overview - Octapharma AG
  • Figure 86: Revenue (US$ Mn) and Y-o-Y Growth, 2015-2017 - Octapharma AG
  • Figure 87: R&D and Selling and Marketing Expenses, (US$ Mn), 2016-2017 - Octapharma AG
  • Figure 88: Year-end Employee Headcount and Y-o-Y Growth, 2015-2017 - Octapharma AG
  • Figure 89: Gross profit (US$ Mn) and Y-o-Y Growth, 2016-2017 - Octapharma AG
  • Figure 90: Product Overview - Portola Pharmaceuticals, Inc.
  • Figure 91: R&D and Selling and Marketing Expenses, (US$ Mn), 2016-2017 - Portola Pharmaceuticals, Inc.
  • Figure 92: Revenue (US$ Mn) and Y-o-Y Growth, 2015-2017 - Portola Pharmaceuticals, Inc.
  • Figure 93: Product Overview - Perosphere Pharmaceuticals Inc.
目次

Title:
Anticoagulant Reversal Drugs Market (Product - Prothrombin Complex Concentrates, Vitamin K, Protamine, Tranexamic Acid, Idarucizumab, AndeXXa; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026.

Overview

The global anticoagulant reversal drugs market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on product, distribution channel, and region. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the overview section. Additionally, the section comprises competitive matrix and company profiles along with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region, thereby presenting a thorough analysis of the overall competitive scenario in the global anticoagulant reversal drugs market.

Key Segments

In terms of product, the global anticoagulant reversal drugs market has been segmented into prothrombin complex concentrates, vitamin K, protamine, tranexamic acid, idarucizumab, AndeXXa, and others. Based on distribution channel, the global market has been classified into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment is anticipated to expand at a high CAGR during the forecast period. The market has been analyzed based on price variations, technology trend, and presence of key players. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.

Regional Outlook

Geographically, the global anticoagulant reversal drugs market has been segmented into five major regions: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East (South Africa, GCC Countries, Israel, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries/sub-regions have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in Report

The report also profiles the major players in the market in terms of attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Key companies profiled in the global anticoagulant reversal drugs market include Bausch Health Companies, Inc., Pfizer, Inc., Fresenius Kabi AG, Amneal Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, CSL Limited, Octapharma AG, Portola Pharmaceuticals, Inc., and Perosphere Pharmaceuticals, Inc.

The global anticoagulant reversal drugs market has been segmented as follows:

Global Anticoagulant Reversal Drugs Market, by Product

  • Prothrombin Complex Concentrates (PCC)
  • Vitamin K
  • Protamine
  • Tranexamic Acid
  • Idarucizumab
  • AndeXXa
  • Others

Global Anticoagulant Reversal Drugs Market, by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Global Anticoagulant Reversal Drugs Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Australia
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • South Africa
    • GCC Countries
    • Israel
    • Rest of Middle East & Africa

Table of Contents

1. Preface

  • 1.1. Report Scope and Market Segmentation
  • 1.2. Research Highlights

2. Assumptions and Acronyms Used

3. Research Methodology

4. Executive Summary

5. Market Overview

  • 5.1. Product Overview
  • 5.2. Market Dynamics
    • 5.2.1. Drivers
      • 5.2.1.1. Rise in the prevalence of atrial fibrillation in aging population
      • 5.2.1.2. Increase in the prevalence of ICH and GI hemorrhages
      • 5.2.1.3. NTAP status for specific drugs
    • 5.2.2. Restraints
      • 5.2.2.1. Challenges associated with the development of anticoagulant reversal drugs
      • 5.2.2.2. Risk associated with reversing anticoagulation
    • 5.2.3. Opportunities
      • 5.2.3.1. Unmet clinical needs
      • 5.2.3.2. Untapped market in emerging economies
    • 5.2.4. Global Anticoagulant Reversal Drugs Market Value (US$ Mn) Forecast, 2016?2026
    • 5.2.5. Global Anticoagulant Reversal Drugs Market Outlook
    • 5.2.6. Key Industry Developments
    • 5.2.7. Regulatory Scenario
    • 5.2.8. Reimbursement Scenario
    • 5.2.9. Pipeline Analysis
    • 5.2.10. Healthcare Overview

6. Global Anticoagulant Reversal Drugs Market Analysis, by Product

  • 6.1. Introduction
  • 6.2. Global Anticoagulant Reversal Drugs Market Value Share Analysis, by Product
  • 6.3. Global Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2016?2026
    • 6.3.1. Prothrombin Complex Concentrates (PCC)
    • 6.3.2. Vitamin K
    • 6.3.3. Protamine
    • 6.3.4. Tranexmic Acid
    • 6.3.5. Idarucizumab
    • 6.3.6. Andexxa
    • 6.3.7. Others
  • 6.4. Market Attractiveness, by Product

7. Global Anticoagulant Reversal Drugs Market Analysis, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Global Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel
  • 7.3. Global Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2016-2026
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Retail Pharmacies
    • 7.3.3. Others
  • 7.4. Market Attractiveness, by Distribution Channel

8. Global Anticoagulant Reversal Drugs Market Analysis, by Region

  • 8.1. Introduction
  • 8.2. Global Anticoagulant Reversal Drugs Market Value Share Analysis, by Region
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness Analysis, by Region

9. North America Anticoagulant Reversal Drugs Market Analysis

  • 9.1. Key Findings
  • 9.2. North America Anticoagulant Reversal Drugs Market Value Forecast, by Country, 2016?2026
    • 9.2.1. U.S.
    • 9.2.2. Canada
  • 9.3. North America Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2016-2026
    • 9.3.1. Prothrombin Complex Concentrates (PCC)
    • 9.3.2. Vitamin K
    • 9.3.3. Protamine
    • 9.3.4. Tranexmic Acid
    • 9.3.5. Idarucizumab
    • 9.3.6. Andexxa
    • 9.3.7. Others
  • 9.4. North America Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2016-2026
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Retail Pharmacies
    • 9.4.3. Others
  • 9.5. North America Market Attractiveness Analysis
    • 9.5.1. By Country
    • 9.5.2. By Product
    • 9.5.3. By Distribution Channel

10. Europe Anticoagulant Reversal Drugs Market Analysis

  • 10.1. Key Findings
  • 10.2. Europe Anticoagulant Reversal Drugs Market Value Forecast, by Country/Sub-region, 2016?2026
    • 10.2.1. U.K.
    • 10.2.2. Germany
    • 10.2.3. France
    • 10.2.4. Italy
    • 10.2.5. Spain
    • 10.2.6. Rest of Europe
  • 10.3. Europe Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2016-2026
    • 10.3.1. Prothrombin Complex Concentrates (PCC)
    • 10.3.2. Vitamin K
    • 10.3.3. Protamine
    • 10.3.4. Tranexmic Acid
    • 10.3.5. Idarucizumab
    • 10.3.6. Andexxa
    • 10.3.7. Others
  • 10.4. Europe Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2016-2026
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Others
  • 10.5. Europe Market Attractiveness Analysis
    • 10.5.1. By Country/Sub-region
    • 10.5.2. By Product
    • 10.5.3. By Distribution Channel

11. Asia Pacific Anticoagulant Reversal Drugs Market Analysis

  • 11.1. Key Findings
  • 11.2. Asia Pacific Anticoagulant Reversal Drugs Market Value Forecast, by Country/Sub-region, 2016?2026
    • 11.2.1. China
    • 11.2.2. Japan
    • 11.2.3. India
    • 11.2.4. Australia
    • 11.2.5. Rest of Asia Pacific
  • 11.3. Asia Pacific Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2016-2026
    • 11.3.1. Prothrombin Complex Concentrates (PCC)
    • 11.3.2. Vitamin K
    • 11.3.3. Protamine
    • 11.3.4. Tranexmic Acid
    • 11.3.5. Idarucizumab
    • 11.3.6. Andexxa
    • 11.3.7. Others
  • 11.4. Asia Pacific Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2016-2026
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Others
  • 11.5. Asia Pacific Market Attractiveness Analysis
    • 11.5.1. By Country/Sub-region
    • 11.5.2. By Product
    • 11.5.3. By Distribution Channel

12. Latin America Anticoagulant Reversal Drugs Market Analysis

  • 12.1. Key Findings
  • 12.2. Latin America Anticoagulant Reversal Drugs Market Value Forecast, by Country/Sub-region, 2016?2026
    • 12.2.1. Brazil
    • 12.2.2. Mexico
    • 12.2.3. Rest of Latin America
  • 12.3. Latin America Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2016-2026
    • 12.3.1. Prothrombin Complex Concentrates (PCC)
    • 12.3.2. Vitamin K
    • 12.3.3. Protamine
    • 12.3.4. Tranexmic Acid
    • 12.3.5. Idarucizumab
    • 12.3.6. Andexxa
    • 12.3.7. Others
  • 12.4. Latin America Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2016-2026
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Others
  • 12.5. Latin America Market Attractiveness Analysis
    • 12.5.1. By Country/Sub-region
    • 12.5.2. By Product
    • 12.5.3. By Distribution Channel

13. Middle East & Africa Anticoagulant Reversal Drugs Market Analysis

  • 13.1. Key Findings
  • 13.2. Middle East & Africa Anticoagulant Reversal Drugs Market Value Forecast, by Country/Sub-region, 2016?2026
    • 13.2.1. GCC Countries
    • 13.2.2. South Africa
    • 13.2.3. Israel
    • 13.2.4. Rest of Middle East & Africa
  • 13.3. Middle East & Africa Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2016-2026
    • 13.3.1. Prothrombin Complex Concentrates (PCC)
    • 13.3.2. Vitamin K
    • 13.3.3. Protamine
    • 13.3.4. Tranexmic Acid
    • 13.3.5. Idarucizumab
    • 13.3.6. Andexxa
    • 13.3.7. Others
  • 13.4. Middle East & Africa Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2016-2026
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Others
  • 13.5. Middle East & Africa Market Attractiveness Analysis
    • 13.5.1. By Country/Sub-region
    • 13.5.2. By Product
    • 13.5.3. By Distribution Channel

14. Competitive Landscape

  • 14.1. Competition Matrix
  • 14.2. Anticoagulant Reversal Drugs Market Share Analysis, by Company (2018)
  • 14.3. Company Profiles
    • 14.3.1. Bausch Health Companies, Inc.
      • 14.3.1.1. Company Overview (Headquarters, Business Segments, Employee Strength)
      • 14.3.1.2. Financial Overview
      • 14.3.1.3. Product Portfolio
      • 14.3.1.4. SWOT Analysis
      • 14.3.1.5. Strategic Overview
    • 14.3.2. Pfizer, Inc.
      • 14.3.2.1. Company Overview (Headquarters, Business Segments, Employee Strength)
      • 14.3.2.2. Financial Overview
      • 14.3.2.3. Product Portfolio
      • 14.3.2.4. SWOT Analysis
    • 14.3.3. Fresenius Kabi AG
      • 14.3.3.1. Company Overview (Headquarters, Business Segments, Employee Strength)
      • 14.3.3.2. Financial Overview
      • 14.3.3.3. Product Portfolio
      • 14.3.3.4. SWOT Analysis
    • 14.3.4. Amneal Pharmaceuticals, Inc.
      • 14.3.4.1. Company Overview (Headquarters, Business Segments, Employee Strength)
      • 14.3.4.2. Product Portfolio
      • 14.3.4.3. SWOT Analysis
      • 14.3.4.4. Strategic Overview
    • 14.3.5. Boehringer Ingelheim GmbH
      • 14.3.5.1. Company Overview (Headquarters, Business Segments, Employee Strength)
      • 14.3.5.2. Financial Overview
      • 14.3.5.3. Product Portfolio
      • 14.3.5.4. SWOT Analysis
      • 14.3.5.5. Strategic Overview
    • 14.3.6. CSL Limited
      • 14.3.6.1. Company Overview (Headquarters, Business Segments, Employee Strength)
      • 14.3.6.2. Financial Overview
      • 14.3.6.3. Product Portfolio
      • 14.3.6.4. SWOT Analysis
    • 14.3.7. Octapharma AG
      • 14.3.7.1. Company Overview (Headquarters, Business Segments, Employee Strength)
      • 14.3.7.2. Financial Overview
      • 14.3.7.3. Product Portfolio
      • 14.3.7.4. SWOT Analysis
    • 14.3.8. Portola Pharmaceuticals, Inc.
      • 14.3.8.1. Company Overview (Headquarters, Business Segments, Employee Strength)
      • 14.3.8.2. Financial Overview
      • 14.3.8.3. Product Portfolio
      • 14.3.8.4. SWOT Analysis
      • 14.3.8.5. Strategic Overview
    • 14.3.9. Perosphere Pharmaceuticals, Inc. (acquired by AMAG Pharmaceuticals, Inc.)
      • 14.3.9.1. Company Overview (Headquarters, Business Segments, Employee Strength)
      • 14.3.9.2. Product Portfolio
      • 14.3.9.3. SWOT Analysis